High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial

2026/07/01 by Gerald Illerhaus, Andrés J M Ferreri, Julia Wendler +59 · 1 voice
Medicine · #CAR-T cell therapy research #CNS Lymphoma Diagnosis and Treatment #Lymphoma Diagnosis and Treatment

paper · doi:10.1016/s0140-6736(26)00917-7

crossref issued 2026/07/01 · crossref published 2026/07/01 · crossref published-print 2026/07/01 · openalex publication_date 2026/07/01 · crossref created 2026/07/22 · openalex created_date 2026/07/23 · crossref deposited 2026/07/23 · crossref indexed 2026/07/23 · openalex updated_date 2026/07/31

Citations

• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Discussions

• 🚨 New trial: MATRix/IELSG43 ➡️ newly diagnosed PCNSL HCT-ASCT vs R-DeVIC consolidation 👉 3y PFS 78% vs 51% (HR 0.43) 👉 3y OS 86% vs 71% (HR 0.46) ✅ Progression risk cut 57%, death risk 54% → prefer [bsky, 0 points, 0 comments]